The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2016 (PDF).
This issue advises that trametinib (Mekinist®) has been associated with an increased risk of gastrointestinal perforation and colitis. Clinicians and patients using this medication should be vigilant for signs and symptoms of gastrointestinal perforation. Patients should be advised to seek urgent medical attention if they develop severe abdominal pain.
This issue also contains a reminder of the letter sent last month to raise awareness of the risks of developmental disorders and congenital malformations associated with valproate use in pregnancy.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« SMC Update - March 2016||Updated advice on the risk of DKA with SGLT2 inhibitors »|